Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of 19F Cell Sense to Image PBMCs
NCT02921373Phase 1Withdrawn
- Start
- Jul 2019
- Primary completion
- Jun 2022
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of CellSense in prostate cancer (PCa) (2 arms). Primary endpoints: Number of participants with treatment-related adverse effects as assessed by CTCAE v4.0 at 12 months and Determine the feasibility of using Cell Sense to detect and monitor the migration of PBMC in humans. Planned start Jul 2019; status: withdrawn.
02
Drugs
CellSense
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02921373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921373.